PEAK6 Investments’s Corbus Pharmaceuticals CRBP Stock Holding History

PEAK6 Investments’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,250	Closed	-$261K	–	3756
2019 Q1	$261K	Sell	1,250 -2,563	-67%	-$565K	﹤0.01%	2794
2018 Q4	$668K	Sell	3,813 -834	-18%	-$166K	﹤0.01%	2101
2018 Q3	$1.05M	Buy	+4,647	New	+$751K	﹤0.01%	1956

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PEAK6 Investments's CRBP Position: Q2 2019 in Review

PEAK6 Investments sold out of Corbus Pharmaceuticals (CRBP) in Q2 2019, closing a stake of 140 shares — an estimated $29K sold.

PEAK6 Investments first reported a position in CRBP in Q3 2018 and held it in 3 quarters. The position peaked at $113K in Q3 2018. 103 funds tracked by Wall St. Rank hold CRBP as of Q2 2019.

PEAK6 Investments reported no remaining Corbus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
PEAK6 Investments sold 140 Corbus Pharmaceuticals shares in Q2 2019, an estimated $29K.
PEAK6 Investments first reported a position in Corbus Pharmaceuticals in Q3 2018 and held it in 3 quarters.
PEAK6 Investments's Corbus Pharmaceuticals position peaked at $113K in Q3 2018.
103 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2019.

Based on PEAK6 Investments's 13F filing for Q2 2019, filed 14 Aug 2019.